OBJECTIVES: The effect of induction chemoradiotherapy (CRT) on bronchial anastomoses remains uncertain. This prospective study aimed to assess the impact of neoadjuvant CRT on mortality, morbidity and survival following circular sleeve lobectomy (SL).
INTRODUCTION
The dreadful prognosis of advanced non-small cell lung cancer (IIIA and IIIB) after surgery has promoted multimodality treatments to achieve better local and systemic control of the disease. Concurrent chemoradiotherapy (CRT) followed by surgery seems to improve survival and resectability rate in downstage advanced tumours despite the controversy [1, 2] . Induction radiation dosage has been increased from 45 to 60 Gy to increase downstage response in these affected mediastinal lymph nodes, apparently without extra postoperative complications [3] . In addition, salvage surgery after radical radiation doses (>59 Gy) is becoming more frequent in the clinical practice, and is relatively safe and reliable even after the 'classical' treatment window of 8 weeks.
Very reliable information exists about the deleterious effect of these CRT schemes when combined with pneumonectomies. The high-mortality rate linked to pneumonectomy compromises long-term survival, and the great loss of respiratory function, more than 30% in almost every case causes a deleterious effect over the quality of life [4, 5] . In this context, sleeve lobectomy (SL) is considered an excellent solution to decrease morbidity and mortality in high-risk patients with central tumours [6, 7] . However, the safety of these techniques in irradiated fields remains uncertain for several reasons: very little information is available, achieving sufficient SL after chemoradio-induction takes long periods of time, and treatment schemes and radiotherapy technology may differ during this time. Conversely, from the technical point of view, distinguishing the fibrosis and inflammation caused by CRT from truly residual tumour infiltration is difficult and tentative, even for the pathologist in the frozen section [8] . Moreover, vascular and bronchial dissection in these treated fields may be extremely difficult in some cases and bronchial healing has been considered likely to be impaired by the radiotherapy [9] . This prospective study aimed to assess the safety of SL after CRT induction in terms of postoperative complications, focusing on anastomotic complications and long-term outcomes.
PATIENTS AND METHODS
Between June 2005 and December 2010, 597 patients were surgically treated for NSCLC in our tertiary centre. All cases meeting hospital lung cancer guidelines for oncological and functional criteria were assessed in a multidisciplinary meeting. Informed consent was obtained from all cases and the hospital ethics committee approved the lung cancer protocol. Patients were prospectively included; preoperative, postoperative and follow-up data were collected.
Eligibility
All patients were <85 years old, with ECOG performance status 0-1 and scheduled for curative sleeve resection. Only circular bronchial and/or vascular anastomosis, excluding other surgical techniques for bronchial stump (bronchi wedge) or artery reconstruction (tangential partial pulmonary arteries suture), were prospectively included. All candidates had a chest computerized tomography (CT) scan and 18F-fluoro-D-glucose positron emission tomography (18FDG-PET/CT). Clinical staging was performed according to the revised TNM system, following 2009 International Association for the Study of Lung Cancer guidelines [10] .
The European Society Thoracic Surgeons Guidelines for Mediastinal Staging and Re-staging was followed [11] . In the absence of positive mediastinal lymph nodes (CTscan short axis >1 cm or 18FDG-PET/CT uptake SUV max >2.5), a thoracotomy for anatomical resection plus systematic mediastinal dissection was performed. Nonetheless, when direct mediastinal invasion, cN1 disease or high-risk patients were suspected, despite negative clinical staging, invasive mediastinal staging was conducted by the most appropriate method available to assess the target station (e.g. EBUS, blind bronchoscopic needle aspiration, mediastinoscopy). Our unit did not perform systematic invasive staging (e.g. mediastinoscopy, EBUS, EUS-FNA) for central tumours staged as cN0 patients, but all cases were assessed individually. All cN2 patients diagnosed preoperatively underwent neoadjuvant CRT, including a scheme of platinum-based chemotherapy and simultaneous radiotherapy (45-60 Gy) delivered to the tumour and the positive mediastinal target station(s) following European recommendations [12] . In the absence of progressive disease, all patients who achieved partial or complete response (tumour and mediastinal nodes previously involved) by CT and 18FDG-PET/CT were individually restaged using the appropriate less invasive method, but mediastinoscopy or re-mediastinoscopy was not systematically performed in total mediastinal response by image (yN0). Patients treated by CRT were scheduled for thoracotomy within the 'therapeutic classical window' defined as the next 8 weeks after radiotherapy. Some of these patients were carefully and individually evaluated in our unit after the classical timing window had passed for several reasons (e.g. referred from other centres, second opinion or complication/delay during the induction therapy). Patients for surgery underwent a sleeve anatomical pulmonary resection and a systematic mediastinal dissection, performed by a consultant thoracic surgeon as recommended by the ESTS guidelines [11] .
All patients were functionally evaluated under hospital guidelines. In brief, resection was considered functionally possible if the predictive postoperative forced expiratory volume in 1 s ( ppoFEV1), calculated on the basis of spirometry and isotopic scanning, was >40% of the predicted value and no major hypoxaemia (<60 mmHg) or hypercapnia (>46 mmHg) existed; it was contraindicated if ppoFEV1 was <30%. After neoadjuvant therapy, all patients were reassessed to search for oncological therapy-related respiratory impairment. In summary, when FEV1 values were between 30 and 40%, patients were considered at relatively high risk, and individual decision was based on evaluation of multiple clinical and functional parameters ( ppoFEV1, PO 2 , PCO 2 , DLCO, age, comorbidities, exercise tests and likelihood of pneumonectomy).
Surgical technique and postoperative care
A flexible bronchoscopy was performed in the operation theatre before thoracotomy to assess endoscopic tumour extension and a bronchial aspirate for analysis is collected. Surgical technique is detailed elsewhere [7, 13] . Briefly, circumferential bronchial or pulmonary artery resection, or both, was performed with the best oncological margins possible using a scalpel. Bronchi manipulation was very gentle in order to protect the blood supply, to preserve the bronchial arteries and to avoid electrocautery on surrounding tissues. Bronchial anastomosis used a continuous running monofilament suture at the bottom of the anastomosis, from the cartilaginous-membranous juncture, the mediastinal face of the bronchus, to the middle of the cartilaginous ring. Interrupted 4/0 monofilament suture, keeping knots outside the bronchus, was used for the remaining cartilaginous and membranous walls. Circular pulmonary artery resection was performed when needed, using 5/0 polypropylene under systemic and local heparinization. Pulmonary artery replacement was performed by cryopreserved allograft when needed. All anastomoses performed in the CRT group were systematically covered by intercostal flaps harvested during the thoracotomy; however, in the non-CRT group, covered flaps were used depending on the surgeon's opinion.
All patients spent the first 24 h after operation in ICU, or until adequate pain relief was achieved and surgical early complication ruled out. Prophylactic low-weight heparin was started 12 h after operation, if bleeding was not excessive. Fibre-optic bronchoscopy was performed routinely at 1 week before discharge and at 1 month and 3 months after hospital discharge, and whenever atelectasis or anastomosis failure was suspected. Operative mortality was defined as death directly related to the surgical procedure or within 30 days of the operation.
Patients underwent adjuvant therapy when considered appropriate (non-CRT group: unexpected pN1-2, tumour bigger than 5 cm or pIIIB and CTR group: pN2 after surgery and failure to downstaging). The site of recurrence was classified as ipsilateral thorax, mediastinal or distant. The cause of death was classified as local recurrence, distant metastasis or other cause or unknown.
Statistical methods
Analyses used SPSS v.11 (SPSS Inc., Chicago, IL, USA). Qualitative variables were compared with χ 2 or Fisher's exact test as THORACIC appropriate, with significance level at P < 0.05. Student's t-test was used to compare parametric data between groups and the Mann-Whitney U-test for non-parametric data. Univariate analysis of all variables was performed first, to identify significant factors for inclusion in a multivariate Cox's regression model. Multivariate analyses of independent prognostic factors were assessed by Cox proportional hazards. Results are presented as estimated relative risk with 95% confidence intervals. KaplanMeier curves were plotted and compared using the log-rank test for univariate analysis.
RESULTS
Among the patients surgically treated in our unit during this period, 126 (21.1%) suffered from a central tumour. Of these, 79 (13%) patients underwent SL and 23 (4%) pneumonectomies. The SL patients were divided into two groups, received induction or not with CRT for downstaging ( Table 1) . CRT patients received chemotherapy and concurrent radiotherapy treatments (Table 2) underwent surgical treatment before 8 weeks if appropriate response was achieved. Four cervical mediastinoscopies were performed to rule out cN2 after induction and two produced a false-negative in CRT patients; all pN2 cases but one had solely station-affected. Final pStage in the CTR group showed a downstage with no pN2 ( pN0 or pN1) in 21 (80%) patients. There were 49 (62%) bronchial reconstruction, 21 (26.5%) bronchial and vascular reconstruction and 9 (11%) solely vascular reconstruction (Table 1) . Right upper lobe was the more frequent location (39 patients, 49%), followed by left upper lobe (24 patients, 30%).
The pN1 vascular or bronchial invasion led to SL in only 9 (12.5%) cases, and vascular reconstruction was needed in only 3. Cryopreserved allograft for pulmonary artery reconstruction was needed in 5 cases, and 12 patients underwent an atypical extended SL. The most frequent procedure was right upper SL plus median lobe, in five cases. These patients did not show significantly more complications than the standard SL (P > 0.05). Eleven (14%) patients in our series were scheduled for sparing techniques, precluding pneumonectomy for functional reasons. Complete resection was achieved and pneumonectomy avoided in all cases. Complete resection (R0) was achieved in all cases.
Postoperative complications occurred in 25 (32%) patients, 16 (30%) non-CRT and 9 (34%) CRT (Table 3 ). Mortality occurred in three (3.8%) patients within the non-CRT group, due to bronchovascular fistula, pulmonary artery thrombosis (reoperation and pneumonectomy and exitus due to pneumonia) and ADRS. There were no significant differences between groups in anastomotic complications or other events studied (P > 0.05). The most frequent complication in both groups was acute respiratory insufficiency, 23 (29%), followed by sputum retention 14 (18%) ( Table 3) . No bronchoscopic stenosis was detected during the follow-up. Bronchial aspiration was taken after the first week during the bronchoscopic review, and 14 (18%) patients received antibiotics appropriate to the bacterium isolated. In addition, one patient showed an inflammatory vascular thrombosis suspected by bronchoscopy, without clinical and CT confirmation. These findings were resolved ad integrum without treatment. Anastomosis was covered in 35 (44%) cases, routinely in CRT. For both groups, pN1 (P = 0.04), vascular reconstruction and upper-left SL (P = 0.03) were independent risk factors for postoperative complications, but not for mortality. No other variable studied was significantly related to increased complications or mortality (P > 0.05).
The patients among both groups eligible for postoperative adjuvant therapy were 19 (24%), 5 in the CTR group and 14 in the non-CTR group. Twenty (32%) patients had systemic recurrence during follow-up. Ten (13%) metastases were CRT group (4 bone, 4 brain and 2 hepatic) and 11 (14%) in the non-CRT group (5 bone metastases, 2 brain metastases, 3 hepatic and 1 adrenal) ( Table 2 ). Only one CRT patient underwent local mediastinal recurrence.
The mean follow-up was 33 ± 17.8 (range 6-67) months. CRT and non-CRT survival rates [means (months), 95% confidence interval] were 36 (25-47) and 55 (49-61) (P = 0.02). Disease-free survival [DFS, means (months)] was 31 (21-41) and 46 (41-52) (P = 0.01) (Fig. 1) . Univariate and multivariate Cox analyses are shown in Table 4 . Univariate and multivariate analyses using a Cox model showed a significant result in favour of non-CRT and age <70 years.
Comment
Despite the controversy, there is evidence that multimodality treatment may benefit survival for IIIA-IIIB NSCLC patients in several situations (e.g. mediastinal sterilization, pneumonectomy avoidance and careful selection of the candidates). Several prospective and multicentre studies have demonstrated the safety of anatomical pulmonary resections after induction with concurrent chemotherapy and radiotherapy [1, 2] even after a high dose (>60 Gy) of radiotherapy [3] . This aggressive induction schemes may expose these surgical candidates to a different variety of complications caused either oncologically (e.g. the extracapsular hilomediastinal lymph nodes, advanced tumours, etc.) or by deleterious effects of these therapies on lung function (ARDS, pneumonia, etc.) or bronchial healing [9] . Solid conclusions have been drawn regarding induction CRT and right pneumonectomy, with a mortality rate between 14 and 43%, mainly related to bronchial dehiscence or ARDS [1, 5] . Shapiro et al. [14] confirmed the independent risk factor of induction therapy, age, limited FEV1, and right-side and congestive heart failure for major morbidity after pneumonectomy. Nevertheless, Weder et al. [15] recently reported 3% mortality after CRT and pneumonectomy, 
THORACIC
A. Gómez-Caro et al. / European Journal of Cardio-Thoracic Surgerywhereas others do not preclude pneumonectomy after neoadjuvant CRT if complete resections can be achieved, despite the risk of post-operative complication [5] . In our experience, pneumonectomy can be considered the first hurdle in achieving significant survival benefit in advanced tumours after neoadjuvant therapy, given the high mortality observed after this operation and the dreadful complications [7] . In addition, pneumonectomies have a deleterious effect on short, immediate and long-term quality of life and pulmonary function [7] . In their phase III trial, Albain et al. [1] did not demonstrate a significant survival difference between the surgical and non-surgical arms after concurrent chemotherapy and radiotherapy, mainly because of the operative mortality rate (26%) after pneumonectomy. On the basis of this finding, the authors did an exploratory matching analysis that lead to the hypothesis that trimodality treatment could be beneficial if a complete resection without pneumonectomy can be done, or if mortality from pneumonectomy can be avoided. SWOG S9900 presents a similar mortality rate (16.7%) in the induction group when compared with surgery alone, with no mortality [16] . Thomas et al. [2] recommend to avoid pneumonectomy after chemoradiation due to the high risk of major complications. In this randomized study, pre-operative chemoradiation in addition to chemotherapy increased pathological response and mediastinal downstaging, but does not improve survival when compared with chemotherapy induction.
Therefore, it seems sensible to assess carefully the value of right pneumonectomy after chemoradiation due to the high mortality and unclear prognosis after induction therapy following this operation.
Our study results show that bronchovascular reconstructive surgery is a reliable, safe and effective alternative to pneumonectomy after CRT [17] [18] [19] , avoiding the terrible related complications and decreasing surgical mortality. These reconstructive techniques were initially developed for functionally limited patients with either benign or malignant lesions to spare lung parenchyma, trying to increase the resection rate in these compromised patients. For oncological outcomes in central tumours, SL is considered least similar to pneumonectomy [6] . Other authors found better short-and long-term results after SL compared with pneumonectomy [6, 7] . The avoidance of pneumonectomy is an even better strategy in the elderly, associating an extensive lung parenchyma resection with high and unacceptable mortality. Right pneumonectomy in patients >70 years has been related to higher mortality [4, 14] . Mortality after SL in patients >70 years has been reported as 6%, significantly lower than pneumonectomy [20] . These candidates have more underlying associated diseases: myocardial revascularization, diabetes, renal insufficiency and COPD. In our series, >36% of the patients were >70 years; spare lung parenchyma and function seems crucial to achieve a low mortality and best possible long-term results [6, 7, 21] . Since 2005, our unit has developed an aggressive strategy to avoid pneumonectomy [7] , based on three principles: first, sparing as much lung parenchyma as possible, even when complex resections of more than a lobe (extended SL) have to be carried out; secondly, using cryopreserved allografts for vascular replacement to save lobes even in intrapulmonary artery replacement and, eventually, in our strategy we do not perform pneumonectomy for any intraoperative or clinical reason (e.g. pN1, CRT, age) except when a complete resection can not be achieved otherwise [13] . In summary, this strategy has allowed us to avoid at least 25% of pneumonectomies in our practice [7] .
Several reports confirm the safety of bronchovascular reconstructions after chemotherapy [8, 18, 19] and CRT [17, 22] ( Table 5 ). In our experience, anastomotic disruption or failure is not related to neoadjuvant treatment, despite the potential healing problems postulated. Rea et al. [23] identified radiation therapy as an early adverse factor for bronchial anastomoses. In their series, the bronchovascular fistula was responsible for 44% of postoperative mortality after radiation. The high rate of bronchial healing complication observed decreased with the systematic use of flaps, at least, in the CRT group. After induction, the most important oncological factors affecting long-term survival are the sterilization of mediastinal lymph nodes and achievement of complete resection. Many studies show that complete resection had a favourable impact on survival [5, 14, 15] , reaching 27% 5-year survival after induction therapy in cIIIA. Incomplete resection offered no benefit over radiotherapy alone [1, 15] . Downstaging of the mediastinal nodes has been documented in several studies as the strongest predictor of survival. The complete lymph node response ( pN0) showed 5-year survival of 35-46% [15, 24] . Our results support these findings, with a survival of 33 and 43% when CRT achieves a mediastinal downstaging.
Local control is similar after pneumonectomy or SL and the pattern of systemic recurrence is, without a doubt, more frequent [6, 23, 25] . In our series, only one patient had a local recurrence but 28% had distant recurrence, the major factor affecting the long-term survival. Milman et al. [17] reported similar survival rates with or without induction. However, in our experience, systemic recurrence was more frequent in CRT patients, and survival significantly worse. Complete mediastinal response (pN0,N1) did not improve survival rate when compared with non-CRT [1, 2] , but these groups showed a better survival compared to the persistent mediastinal lymph node groups.
The study's limitations include the small number of cases, the non-mediastinal re-assessment routinely by mediastinoscopy after induction therapy and lack of uniformity in the timing window. Nevertheless, the authors' experience supports previous results with regard to the safety of SL after concurrent CRT with the largest series reported in the shortest period of time. Anastomotic complications are not increased after neoadjuvant concurrent CRT and these lung parenchyma-sparing techniques offer an excellent strategy to ameliorate postoperative mortality related to pneumonectomy with at least similar long-term survival in central NSCLC. The timing window for surgery after chemoradiation may be considered tentative and surgery can be performed in 'salvage' cases. Locoregional disease control can be achieved by SL after chemoradiation, preserving respiratory function and avoiding pneumonectomy-related complications.
Conflict of interest: none declared. 
